$CBIS Radio Interview: The Company Spoke of Its Market Prioritization

CEO Raymond C. Dabney was interviewed by radio host, Michael Bazsuly about the company and legal/societal progression of cannabis-based treatment initiatives. The company emphasized their strong focus in the pharmaceuticals market. Cannabis Science is working to run clinical trials and develop their formulas in Europe so they can bring well-developed and researched treatments to the FDA for clearance to sell as prescription medicine in U.S. markets.

“One of the things we do not condone is smoking the plant,” said Dabney. The company has consistently held a stern position against smoking marijuana, as there are much safer delivery methods than smoking. The company is working to determine the most effective delivery methods for each type of treatable ailment.

The company also addressed its current position in the stock dividend process. They are currently working directly with FINRA to deliver two separate stock dividends to shareholders. The first dividend is to be sent to shareholders of record as of December 31st, 2010 and the second is to be sent to shareholders of record as of October 9th, 2015. The preliminary filings and definitive filings have already been completed. The company stressed that it is doing everything within its power to expedite the dividend issuance. The company is answering questions and comments from FINRA as they come up. This is an on-going interaction, and the company hopes to finish the process as quickly as possible so it can issue the dividend.

Please click here to listen to the Interview and Radio Show in full:
https://www.youtube.com/watch?v=6DVfSQQFmXs

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ‘safe harbor’ for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.